MA39485A - Méthode de traitement de la dépression et du trouble dépressif majeur - Google Patents
Méthode de traitement de la dépression et du trouble dépressif majeurInfo
- Publication number
- MA39485A MA39485A MA039485A MA39485A MA39485A MA 39485 A MA39485 A MA 39485A MA 039485 A MA039485 A MA 039485A MA 39485 A MA39485 A MA 39485A MA 39485 A MA39485 A MA 39485A
- Authority
- MA
- Morocco
- Prior art keywords
- depressive disorder
- major depressive
- treating depression
- depression
- treating
- Prior art date
Links
- 208000024714 major depressive disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461948529P | 2014-03-05 | 2014-03-05 | |
| US201462061417P | 2014-10-08 | 2014-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA39485A true MA39485A (fr) | 2015-09-11 |
Family
ID=54055831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA039485A MA39485A (fr) | 2014-03-05 | 2015-03-04 | Méthode de traitement de la dépression et du trouble dépressif majeur |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20170137880A1 (fr) |
| EP (1) | EP3114239A4 (fr) |
| JP (1) | JP2017512204A (fr) |
| KR (1) | KR20160127126A (fr) |
| CN (1) | CN106536751A (fr) |
| AU (1) | AU2015227296A1 (fr) |
| CA (1) | CA2940683A1 (fr) |
| IL (1) | IL247379A0 (fr) |
| MA (1) | MA39485A (fr) |
| MX (1) | MX2016011384A (fr) |
| RU (1) | RU2016138574A (fr) |
| WO (1) | WO2015134585A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017087735A1 (fr) * | 2015-11-18 | 2017-05-26 | Millennium Pharmaceuticals, Inc. | Procédé de traitement de la maladie de crohn |
| US20190216803A1 (en) | 2017-03-30 | 2019-07-18 | Rundle Research, LLC | Methods of treating depression with vortioxetine |
| WO2018182639A1 (fr) * | 2017-03-30 | 2018-10-04 | Rundle Research, LLC | Méthodes de traitement de la dépression |
| EP3909600A1 (fr) * | 2020-05-12 | 2021-11-17 | International Centre For Genetic Engineering And Biotechnology - ICGEB | Protéine emid2 en tant que traitement anticancéreux |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090028712A (ko) * | 2006-06-16 | 2009-03-19 | 하. 룬트벡 아크티에 셀스카브 | 인지기능 장애의 치료를 위한, 세로토닌 재흡수, 5-ht3 및 5-ht1a 활성이 조합된 화합물로서의 1-[2-(2,4-디메틸페닐술파닐)-페닐]피페라진 |
| EP2581458A3 (fr) * | 2008-01-17 | 2013-07-17 | Suregene LLC | Marqueurs génétiques de maladie mentale |
| US20140045915A1 (en) * | 2010-08-31 | 2014-02-13 | The General Hospital Corporation | Cancer-related biological materials in microvesicles |
| EP2622101A4 (fr) * | 2010-10-01 | 2014-04-02 | Rigshospitalet | Variations génétiques du gène du récepteur d'interleukine-6 permettant de prédire la réponse de patients au traitement basé sur des inhibiteurs dudit récepteur d'interleukine-6 |
| US9243464B2 (en) * | 2011-02-10 | 2016-01-26 | Baker Hughes Incorporated | Flow control device and methods for using same |
| WO2012109565A1 (fr) * | 2011-02-10 | 2012-08-16 | Neurotherics, Llc | Identification génétique de réponse à des médicaments antidépresseurs |
| EP2780467B1 (fr) * | 2011-11-14 | 2018-10-17 | Alfasigma S.p.A. | Dosages et procédés pour la sélection d'un schéma thérapeutique pour un sujet atteint d'une dépression |
-
2015
- 2015-03-04 MX MX2016011384A patent/MX2016011384A/es unknown
- 2015-03-04 US US15/123,072 patent/US20170137880A1/en not_active Abandoned
- 2015-03-04 JP JP2016554883A patent/JP2017512204A/ja active Pending
- 2015-03-04 RU RU2016138574A patent/RU2016138574A/ru not_active Application Discontinuation
- 2015-03-04 AU AU2015227296A patent/AU2015227296A1/en not_active Abandoned
- 2015-03-04 KR KR1020167027125A patent/KR20160127126A/ko not_active Withdrawn
- 2015-03-04 CN CN201580023401.1A patent/CN106536751A/zh active Pending
- 2015-03-04 MA MA039485A patent/MA39485A/fr unknown
- 2015-03-04 EP EP15758563.9A patent/EP3114239A4/fr not_active Withdrawn
- 2015-03-04 CA CA2940683A patent/CA2940683A1/fr not_active Abandoned
- 2015-03-04 WO PCT/US2015/018701 patent/WO2015134585A1/fr not_active Ceased
-
2016
- 2016-08-21 IL IL247379A patent/IL247379A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL247379A0 (en) | 2016-11-30 |
| RU2016138574A3 (fr) | 2018-10-12 |
| US20170137880A1 (en) | 2017-05-18 |
| RU2016138574A (ru) | 2018-04-06 |
| WO2015134585A1 (fr) | 2015-09-11 |
| CN106536751A (zh) | 2017-03-22 |
| CA2940683A1 (fr) | 2015-09-11 |
| MX2016011384A (es) | 2017-05-01 |
| EP3114239A4 (fr) | 2017-10-11 |
| JP2017512204A (ja) | 2017-05-18 |
| EP3114239A1 (fr) | 2017-01-11 |
| AU2015227296A1 (en) | 2016-09-08 |
| KR20160127126A (ko) | 2016-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290994A (en) | Methods of diagnosing and treating conduct disorder | |
| IL246678A0 (en) | Azepane derivatives and methods of treating hepatitis b infections | |
| EP3463350A4 (fr) | Méthode de traitement de la fibrose hépatique | |
| EP3341080A4 (fr) | Méthode de traitement du cancer | |
| EP3288383A4 (fr) | Méthodes de traitement du cancer | |
| EP3380121A4 (fr) | Méthode de traitement de troubles oculaires | |
| IL249071B (en) | Bleaching and shive reduction process for non-wood fibers | |
| EP3423488A4 (fr) | Méthodes de traitement du cancer | |
| EP3391873A4 (fr) | Procédé et ensemble de traitement capillaire | |
| EP3375440A4 (fr) | Méthode de traitement de la mucosite | |
| LT3174394T (lt) | Augalo inokuliavimo būdas | |
| EP3522934A4 (fr) | Compositions et méthode pour le traitement de la rénopathie | |
| EP3389634A4 (fr) | Méthodes de traitement du cancer | |
| EP3405203A4 (fr) | Méthodes de traitement du cancer | |
| EP3630732A4 (fr) | Méthode et molécules | |
| PL3393468T3 (pl) | Metody leczenia niedoboru odporności | |
| EP3440112A4 (fr) | Méthodes de traitement du cancer | |
| DK3233071T3 (da) | Fremgangsmåde til behandling eller forebyggelse af Ras-medierede sygdomme | |
| EP3313417A4 (fr) | Méthodes de traitement de troubles auto-immuns et allo-immuns | |
| EP3448365A4 (fr) | Méthode de traitement de la constipation | |
| IL257764B (en) | Methods for treatment of diseases | |
| EP3331499A4 (fr) | Composition et méthode de traitement de troubles métaboliques | |
| EP3389652A4 (fr) | Méthodes de traitement du cancer | |
| MA41462A (fr) | Méthode de traitement de maladies | |
| MA41636A (fr) | Méthode de traitement de la cholangite sclérosante primitive |